Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AD
ADC Therapeutics SA
ADCT
Mkt Cap
$179.4M
Volume
657.37K
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AD
ADCT
AD
ADC Therapeutics SA
ADCT
News
·
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Mkt Cap
$178.7M
Volume
657.37K
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Insider
Filings
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating ADC Therapeutics for potential securities fraud following the December 3, 2025 announcement of LOTIS-7 trial data. Despite positive framing, the press release disclosed adverse events in two patients and cytokine release syndrome in 36.7% of patients, triggering a 14.13% stock price decline to $3.95 per share.
GlobeNewswire Inc. · Jan 13, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Graphic Packaging Holding Company - GPK
Pomerantz LLP announced investigations into potential securities fraud at Graphic Packaging Holding Company, Fermi Inc., and ADC Therapeutics SA. Graphic Packaging specifically lowered its full-year earnings guidance on December 8, 2025, citing production curtailments, resulting in an 8.66% stock price decline to $14.23 per share.
GlobeNewswire Inc. · Dec 30, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics following the December 3, 2025 announcement of LOTIS-7 trial data. Despite positive framing, the data revealed adverse events in two patients and cytokine release syndrome in 36.7% of patients, triggering a 14.13% stock price decline to $3.95 per share.
GlobeNewswire Inc. · Dec 30, 2025
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
Analysts forecast the global oncology drug market to exceed $900 billion by 2034, with biotech firms like Oncolytics, Teva, Citius, ADC Therapeutics, and OS Therapies driving cancer treatment innovation amid potential NCI funding cuts.
Benzinga · Jun 26, 2025
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight
The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, monoclonal antibodies, and personalized medicine is transforming treatment outcomes.
GlobeNewswire Inc. · May 12, 2025
Cancer Antibody Drug Conjugates Market, Drugs Approval & Clinical Trials Report 2024 - A US$ 50 Billion+ Market Opportunity By 2030
The global cancer antibody drug conjugates market is a rapidly evolving segment of the cancer therapeutics landscape, with 16 approved products and a market opportunity exceeding $50 billion by 2030. The market is characterized by a competitive landscape, with substantial development efforts targeting multiple cancer types, particularly lung cancer and breast cancer.
GlobeNewswire Inc. · Oct 31, 2024
ADC Therapeutics berichtet über Finanzergebnisse des zweiten Quartals 2024 und gibt aktuelle Informationen zum Geschäftsbetrieb bekannt
ADC Therapeutics reported Q2 2024 financial results, including net product sales of $17.0 million for ZYNLONTA and progress in clinical trials. The company achieved commercial profitability for ZYNLONTA in the first half of 2024 and expects to complete enrollment for the LOTIS-5 study by the end of 2024.
GlobeNewswire Inc. · Aug 6, 2024
Antibody Drug Conjugates Market Insights 2018-2023 and - GlobeNewswire
The global antibody drug conjugates market is expected to grow from $10.32 billion in 2023 to $77.97 billion in 2033, driven by factors such as the increasing prevalence of cancer and aging population. The market is highly concentrated, with the top 10 players accounting for 99.26% of the market share.
GlobeNewswire Inc. · Jul 12, 2024
ADC Therapeutics gewährt neuen Mitarbeitern Zuteilungen im Rahmen des Anreizplans
LAUSANNE, Schweiz, July 02, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) hat heute bekanntgegeben, dass das Unternehmen sechs neuen Mitarbeitern am 1. Juli 2024 Zuteilungen für Optionen auf den Erwerb von insgesamt 172.400 Stammaktien des Unternehmens (jeweils eine „Zuteilung“) gewährt hat. Mit den Zuteilungen wurde den Mitarbeitern ein wesentlicher Anreiz für ihre Beschäftigung angeboten. Die Zuteilungen wurden vom Vergütungsausschuss des Unternehmensvorstands im Rahmen des Anreizplans des Unternehmens genehmigt. Damit sollen die Empfänger zu Spitzenleistungen motiviert und belohnt werden und einen wesentlichen Beitrag zum Erfolg des Unternehmens leisten. Die Bewilligung der Zuteilungen erfolgte unter Berufung auf die Ausnahmeregelung für Beschäftigungsanreize gemäß Regel 303A.08 des NYSE Listed Company Manual. Das Unternehmen veröffentlicht diese Pressemitteilung in Übereinstimmung mit Regel 303A.08. Die Zuteilungen werden zu 25 % am ersten Jahrestag des Zuteilungsdatums und zu 1/48 der Gesamtzahl der den Zuteilungen unterliegenden Aktien an jedem darauffolgenden monatlichen Jahrestag des Zuteilungsdatums unverfallbar und können ausgeübt werden, sodass die gesamte Zuteilung am vierten Jahrestag des Zuteilungsdatums unverfallbar wird, sofern das Beschäftigungsverhältnis mit dem Unternehmen fortgesetzt wird.
GlobeNewswire Inc. · Jul 2, 2024
ADC Therapeutics tritt demnächst den Indizes Russell 2000® und Russell 3000® bei
LAUSANNE, Schweiz, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) hat heute bekanntgegeben, dass das Unternehmen nach Abschluss der jährlichen Neukonstituierung der Russell US-Benchmark-Indizes mit der Eröffnung der US-amerikanischen Aktienmärkte am 1. Juli 2024 dem Russell 2000® Index und dem breiter gefächerten Russell 3000® Index beitritt.
GlobeNewswire Inc. · Jun 27, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AD
ADCT
ADC Therapeutics SA
Buy
Sell
Market
Limit
Soon
ADCT
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ADCT yet.
Related Tickers
Earnings